{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:07:26Z","timestamp":1786993646017,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015406","name":"Tianjin Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["23JCYBJC01060"],"award-info":[{"award-number":["23JCYBJC01060"]}],"id":[{"id":"10.13039\/501100015406","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["T-B-105"],"award-info":[{"award-number":["T-B-105"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-I2M-1-041"],"award-info":[{"award-number":["2021-I2M-1-041"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010041","name":"Tianjin Municipal Science and Technology Committee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82341213"],"award-info":[{"award-number":["82341213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2021YFC2500300"],"award-info":[{"award-number":["2021YFC2500300"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.leukres.2025.107733","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T20:14:00Z","timestamp":1749154440000},"page":"107733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Clinical features and treatment response to TKIs in chronic myeloid leukemia patients with atypical BCR::ABL1 transcripts"],"prefix":"10.1016","volume":"155","author":[{"given":"Haoren","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9153-097X","authenticated-orcid":false,"given":"Cong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benfa","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runxia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchang","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-9151","authenticated-orcid":false,"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2025.107733_bib1","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2025.107733_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.669469","article-title":"Impact of the breakpoint region on the leukemogenic potential and the TKI responsiveness of atypical BCR-ABL1 transcripts","volume":"12","author":"Massimino","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.leukres.2025.107733_bib3","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/1097-0142(19950915)76:6<992::AID-CNCR2820760612>3.0.CO;2-L","article-title":"The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations","volume":"76","author":"Verschraegen","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2025.107733_bib4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ajh.24774","article-title":"The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib","volume":"92","author":"Castagnetti","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2025.107733_bib5","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1002\/cncr.31408","article-title":"The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia","volume":"124","author":"Ercaliskan","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2025.107733_bib6","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107733_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.62","article-title":"Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia","volume":"7","author":"Gong","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2025.107733_bib8","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1080\/10428194.2019.1607329","article-title":"Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts","volume":"60","author":"Xue","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2025.107733_bib9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.trsl.2006.07.002","article-title":"Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR","volume":"148","author":"Goh","year":"2006","journal-title":"Transl. Res."},{"key":"10.1016\/j.leukres.2025.107733_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1590\/S1415-47572010005000037","article-title":"Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients","volume":"33","author":"Osman","year":"2010","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.leukres.2025.107733_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/ijlh.12616","article-title":"Frequency of rare BCR - ABL 1 fusion transcripts in chronic myeloid leukemia patients","volume":"39","author":"Arun","year":"2017","journal-title":"Int. J. Lab Hematol."},{"key":"10.1016\/j.leukres.2025.107733_bib12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/bjh.15453","article-title":"Prevalence and outcomes of uncommon BCR - ABL 1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre","volume":"182","author":"Qin","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2025.107733_bib13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.24591","article-title":"A population-based study of chronic myeloid leukemia patients treated with imatinib in first line","volume":"92","author":"Castagnetti","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2025.107733_bib14","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2015.152","article-title":"Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib","volume":"29","author":"Castagnetti","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107733_bib15","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 european countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107733_bib16","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","article-title":"ABL study group et al. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview","volume":"33","author":"International","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107733_bib17","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1200\/JCO.2013.51.1188","article-title":"Molecular response of e19a2 bcr-abl1 chronic myeloid leukemia with double Philadelphia chromosome to dasatinib","volume":"34","author":"Ikeda","year":"2016","journal-title":"JCO"},{"key":"10.1016\/j.leukres.2025.107733_bib18","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1182\/blood-2009-07-234666","article-title":"Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107733_bib19","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1182\/blood-2009-02-204693","article-title":"Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance","volume":"114","author":"Verma","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107733_bib20","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","article-title":"European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia","volume":"37","author":"Cross","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107733_bib21","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107733_bib22","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.leukres.2025.107733_bib23","article-title":"BCR-JAK2 fusion as a result of a translocation (9;22)(p24;q11.2) in a patient with CML-like myeloproliferative disease","volume":"5","author":"Elnaggar","year":"2012","journal-title":"Mol. Cytogenet"},{"key":"10.1016\/j.leukres.2025.107733_bib24","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) \u2013 a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107733_bib25","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1182\/blood.V87.12.5213.bloodjournal87125213","article-title":"p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias","volume":"87","author":"van Rhee","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107733_bib26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/gcc.22263","article-title":"Molecular characterization and follow-up of five CML patients with new BCR\u2013ABL 1 fusion transcripts","volume":"54","author":"Huet","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.leukres.2025.107733_bib27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2141.2000.02042.x","article-title":"A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia","volume":"109","author":"Branford","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2025.107733_bib28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ajh.20138","article-title":"Second case of CML with aberrant BCR-ABL fusion transcript (e8\/a2) with insertion of an inverted ABL intron 1b sequence","volume":"77","author":"Sugimoto","year":"2004","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2025.107733_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231205637","article-title":"Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor","volume":"14","author":"Park","year":"2023","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.leukres.2025.107733_bib30","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107733_bib31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107733_bib32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107733_bib33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0950-3536(97)80003-0","article-title":"BCR-ABL gene variants","volume":"10","author":"Melo","year":"1997","journal-title":"Baillieres Clin. Haematol."},{"key":"10.1016\/j.leukres.2025.107733_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jmoldx.2024.11.003","article-title":"BCR::ABL1 deep molecular response quantification and transcript type identification in chronic myeloid leukemia using a US food and drug Administration-Approved Droplet-Based digital PCR assay","volume":"27","author":"Kockerols","year":"2025","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.leukres.2025.107733_bib35","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/s41375-022-01612-2","article-title":"Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy","volume":"36","author":"Salmon","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107733_bib36","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1038\/sj.leu.2403079","article-title":"BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis","volume":"17","author":"Schultheis","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107733_bib37","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/sj.leu.2403604","article-title":"e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants?","volume":"19","author":"Demehri","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107733_bib38","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1084\/jem.189.8.1229","article-title":"Signal transducer and activator of transcription (STAT)5 activation by BCR\/ABL is dependent on intact src homology (SH)3 and SH2 domains of BCR\/ABL and is required for leukemogenesis","volume":"189","author":"Nieborowska-Skorska","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.leukres.2025.107733_bib39","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2002-03-0930","article-title":"CML with an e1a3 BCR-ABL fusion: rare, benign, and a potential diagnostic pitfall","volume":"100","author":"Al-Ali","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107733_bib40","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V91.2.406","article-title":"The SH3 domain contributes to BCR\/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing","volume":"91","author":"Skorski","year":"1998","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:43:41Z","timestamp":1777488221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625000931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":40,"alternative-id":["S0145212625000931"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107733","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical features and treatment response to TKIs in chronic myeloid leukemia patients with atypical BCR::ABL1 transcripts","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107733"}}